TY - JOUR
T1 - Prospective validation that vulnerable plaque associated with major adverse outcomes have larger plaque volume, less dense calcium, and more non-calcified plaque by quantitative, three-dimensional measurements using intravascular ultrasound with radiofrequency backscatter analysis
T2 - Results from the ATLANTA i study
AU - Vazquez-Figueroa, Jesus G.
AU - Rinehart, Sarah
AU - Qian, Zhen
AU - Joshi, Parag H.
AU - Sharma, Abhinav
AU - Lee, James
AU - Anderson, Hunt
AU - Murrieta, Laura
AU - Wilmer, Charles
AU - Carlson, Harold
AU - Taylor, Kenneth
AU - Ballard, William
AU - Karmpaliotis, Dimitri
AU - Kalynych, Anna
AU - Brown, Charles
AU - Voros, Szilard
N1 - Funding Information:
Szilard Voros received research grants from Abbott Vascular, Volcano Inc., Siemens Medical Solutions, Vital Images, Toshiba America Medical Systems, Merck Inc., and Abbott Laboratories. S.V. has Speaker's Bureau, Consulting, and Advisory Board Memberships in Vital Images, Toshiba America Medical Systems, and Merck Inc. S.V. is the owner, president, and CEO of Integrated Cardiovascular Research Group, LLC; the CEO of Global Genomics Group; and the Chief Academic Officer of HDL, Inc.
Funding Information:
Funding The current study (ATLANTA; NCT# 00817102) was an investigator-initiated and investigator-sponsored study funded primarily by Abbott Vascular and Volcano, Inc., Siemens Medical Solutions, and Vital Images, and Toshiba America Medical Systems contributed partial and additional funding to the study.
Funding Information:
Dimitri Karmpaliotis received grant support from Medtronic; D.K. has Speakers' Bureau and Consulting memberships in Abbott Vascular and Bridgepoint Medical.
PY - 2013/10
Y1 - 2013/10
N2 - Whether quantitative, two-dimensional, and three-dimensional plaque measurements by intravascular ultrasound with radiofrequency backscatter (IVUS/VH) are different between intermediate lesions with or without major adverse cardiovascular events (MACE) is unknown. IVUS/VH-derived parameters were compared in 60 patients with an intermediate coronary lesion (40-70 %) between lesions that did or did not result in MACE over 12 months. IVUS/VH measurements were done at the site of the minimal lumen area (MLA) and on a per-plaque basis, defined by 40 % plaque burden. Pre-specified, adjudicated MACE events occurred in 5 of 60 patients (8.3 %). MACE lesions had larger plaque burden (65 % vs. 53 %, p = 0.004), less dense calcium (6.6 % vs. 14.7 %, p = 0.05), and more non-calcified plaque, mostly fibrofatty kind (17.6 % vs. 10 %, p = 0.02). Intermediate coronary lesions associated with MACE at 12 months have more plaque, less dense calcium, and more non-calcified plaque, particularly fibrofatty tissue by IVUS/VH.
AB - Whether quantitative, two-dimensional, and three-dimensional plaque measurements by intravascular ultrasound with radiofrequency backscatter (IVUS/VH) are different between intermediate lesions with or without major adverse cardiovascular events (MACE) is unknown. IVUS/VH-derived parameters were compared in 60 patients with an intermediate coronary lesion (40-70 %) between lesions that did or did not result in MACE over 12 months. IVUS/VH measurements were done at the site of the minimal lumen area (MLA) and on a per-plaque basis, defined by 40 % plaque burden. Pre-specified, adjudicated MACE events occurred in 5 of 60 patients (8.3 %). MACE lesions had larger plaque burden (65 % vs. 53 %, p = 0.004), less dense calcium (6.6 % vs. 14.7 %, p = 0.05), and more non-calcified plaque, mostly fibrofatty kind (17.6 % vs. 10 %, p = 0.02). Intermediate coronary lesions associated with MACE at 12 months have more plaque, less dense calcium, and more non-calcified plaque, particularly fibrofatty tissue by IVUS/VH.
KW - Cardiac events
KW - Intravascular ultrasound
KW - Vulnerable plaque
UR - http://www.scopus.com/inward/record.url?scp=84885642866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84885642866&partnerID=8YFLogxK
U2 - 10.1007/s12265-013-9473-0
DO - 10.1007/s12265-013-9473-0
M3 - Article
C2 - 23695823
AN - SCOPUS:84885642866
SN - 1937-5387
VL - 6
SP - 762
EP - 771
JO - Journal of cardiovascular translational research
JF - Journal of cardiovascular translational research
IS - 5
ER -